Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial
Digestive Diseases and Sciences, ISSN: 1573-2568, Vol: 61, Issue: 3, Page: 852-860
2016
- 25Citations
- 35Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations25
- Citation Indexes25
- 25
- CrossRef20
- Captures35
- Readers35
- 35
Article Description
Background: The pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC). In a murine model, relamorelin decreased excitability of colonic circular smooth muscle cells and colonic intraluminal pressure. Aim: To determine short-term effects of relamorelin on colonic motility measured by barostat and multilumen manometry in CC. Methods: In a placebo-controlled, single-dose, double-blind, randomized study in patients with CC, we investigated the motor effects of relamorelin, 100 μg, SQ (12 patients) compared to placebo SQ (six patients). A motility-barostat balloon assembly was used to measure colonic compliance; tone and phasic pressure activity were measured before and after a 1000-kcal milkshake meal (administered ~60 min post-medication). Overall “background” phasic pressure activity was assessed by: average amplitude and motility index (MI = ln[sum amplitudes × #contractions + 1]) over defined periods. High-amplitude propagating contractions (HAPCs) were characterized by amplitude >75 mmHg and propagating contractions >50 mmHg; both were propagated over at least 10 cm. Postprandial HAPCs were the primary end point. The study sample had 80 % power to detect an increase of 3.3 HAPCs in the hour post-meal. Results: Relamorelin, 100 μg, significantly induced more pre-meal propagated contractions [PCs of either >50 or >75 mmHg] compared to placebo (p < 0.05). Relamorelin also induced more post-meal PCs >50 or >75 mmHg than placebo. Relamorelin did not significantly alter colonic compliance, fasting or postprandial phasic pressure activity (20 min pre-meal fasting MI) or tone, and 60 min postprandial phasic pressure amplitude or MI, or tone. Conclusions: Relamorelin stimulates propagated colonic contractions without alteration of background irregular contractions in CC. ClinicalTrial.Gov registration number: NCT 01781104.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84958872323&origin=inward; http://dx.doi.org/10.1007/s10620-015-3876-5; http://www.ncbi.nlm.nih.gov/pubmed/26467700; https://clinicaltrials.gov/ct2/show/NCT01781104; https://facultyopinions.com/prime/725851173#eval793521247; http://dx.doi.org/10.3410/f.725851173.793521247; http://link.springer.com/10.1007/s10620-015-3876-5; https://dx.doi.org/10.1007/s10620-015-3876-5; https://link.springer.com/article/10.1007/s10620-015-3876-5; https://link.springer.com/content/pdf/10.1007%2Fs10620-015-3876-5.pdf; http://link.springer.com/content/pdf/10.1007/s10620-015-3876-5.pdf; http://link.springer.com/article/10.1007%2Fs10620-015-3876-5; http://link.springer.com/article/10.1007/s10620-015-3876-5/fulltext.html; http://link.springer.com/content/pdf/10.1007/s10620-015-3876-5
Faculty Opinions Ltd
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know